Trial Profile
Japanese phase II study in untreated patients with CD20 positive B-cell non-Hodgkin's lymphoma evaluating safety of 90-minute infusion of rituximab.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions
- Sponsors Zenyaku Kogyo
- 19 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 03 Aug 2017 New trial record